Mind Medicine (MindMed) Inc. [NASDAQ: MNMD] plunged by -$0.05 during the normal trading session on Tuesday and reaching a high of $3.35 during the day while it closed the day at $3.19. The company report on May 24, 2021 that MindMed Announces Launch of Collaboration with Nextage Therapeutics’ Brain Targeting Liposome System.
MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading clinical stage psychedelic medicine company, and Nextage Therapeutics (TASE: NXTG), an Israeli innovative drug development company, announce the execution of a Memorandum of Understanding (the “MOU”) regarding the launch of an exclusive collaborative development program to optimize the delivery of certain psychedelic drug candidates, leveraging Nextage’s proprietary Brain Targeting Liposome System (BTLS) delivery technology, for which it has an exclusive license. MindMed and Nextage will initially collaborate to optimize the delivery of drug products based on noribogaine, and ultimately other ibogaine derivatives, and will share development costs and intellectual property arising from the collaboration.
The BTLS technology is an innovative drug delivery system designed to allow the targeted delivery of active pharmaceutical ingredients (APIs) through the Blood Brain Barrier. BTLS is designed to reduce exposure to the active material outside of the brain, reducing potential risks, intended to substantially lower API concentrations and increasing efficacy.
Mind Medicine (MindMed) Inc. stock has also loss -9.12% of its value over the past 7 days. However, MNMD stock has declined by -15.61% in the 3 months of the year. Over the past six months meanwhile, it has gained 155.20% and gained 4.59% year-on date.
The market cap for MNMD stock reached $1.04 billion, with 326.13 million shares outstanding and 286.31 million shares in the current float. Compared to the average trading volume of 6.76M shares, MNMD reached a trading volume of 5492188 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Mind Medicine [MindMed] Inc. [MNMD]:
The Average True Range (ATR) for Mind Medicine (MindMed) Inc. is set at 0.47
MNMD stock trade performance evaluation
Mind Medicine (MindMed) Inc. [MNMD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -9.12. With this latest performance, MNMD shares dropped by -31.98% in over the last four-week period, additionally plugging by 155.20% over the last 6 months – not to mention a rise of 692.35% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MNMD stock in for the last two-week period is set at 48.75, with the RSI for the last a single of trading hit 46.17, and the three-weeks RSI is set at 49.84 for Mind Medicine (MindMed) Inc. [MNMD]. The present Moving Average for the last 50 days of trading for this stock 3.01, while it was recorded at 3.42 for the last single week of trading, and 2.16 for the last 200 days.
Mind Medicine [MindMed] Inc. [MNMD]: An insightful look at the core fundamentals
Mind Medicine [MindMed] Inc. [MNMD]: Insider Ownership positions
There are presently around $1 million, or 0.57% of MNMD stock, in the hands of institutional investors. The top three institutional holders of MNMD stocks are: TRU INDEPENDENCE LLC with ownership of 167,293, which is approximately 48.45% of the company’s market cap and around 6.56% of the total institutional ownership; GOFEN & GLOSSBERG LLC /IL/, holding 72,500 shares of the stock with an approximate value of $0.23 million in MNMD stocks shares; and FNY INVESTMENT ADVISERS, LLC, currently with $64000.0 in MNMD stock with ownership of nearly New of the company’s market capitalization.
5 institutional holders increased their position in Mind Medicine (MindMed) Inc. [NASDAQ:MNMD] by around 93,600 shares. Additionally, 1 investors decreased positions by around 2,249 shares, while 1 investors held positions by with 177,444 shares. The mentioned changes placed institutional holdings at 273,293 shares, according to the latest SEC report filing. MNMD stock had 3 new institutional investments in for a total of 31,000 shares, while 0 institutional investors sold positions of 0 shares during the same period.